388 related articles for article (PubMed ID: 7510098)
41. Expression of myelin protein genes in the developing brain.
Campagnoni AT; Sorg B; Roth HJ; Kronquist K; Newman SL; Kitamura K; Campagnoni C; Crandall B
J Physiol (Paris); 1987; 82(4):229-38. PubMed ID: 2460618
[TBL] [Abstract][Full Text] [Related]
42. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.
Fukaura H; Kent SC; Pietrusewicz MJ; Khoury SJ; Weiner HL; Hafler DA
J Clin Invest; 1996 Jul; 98(1):70-7. PubMed ID: 8690806
[TBL] [Abstract][Full Text] [Related]
43. Differences between T-cell reactivities to major myelin protein-derived peptides in opticospinal and conventional forms of multiple sclerosis and healthy controls.
Minohara M; Ochi H; Matsushita S; Irie A; Nishimura Y; Kira J
Tissue Antigens; 2001 May; 57(5):447-56. PubMed ID: 11556969
[TBL] [Abstract][Full Text] [Related]
44. Anti-myelin basic protein and anti-proteolipid protein antibody-secreting cells in the cerebrospinal fluid of patients with acute optic neuritis.
Sellebjerg FT; Frederiksen JL; Olsson T
Arch Neurol; 1994 Oct; 51(10):1032-6. PubMed ID: 7524468
[TBL] [Abstract][Full Text] [Related]
45. Detection of antibodies to central nervous system antigens by solid phase radioimmunoassay.
Linthicum DS; Mackay IR; Wilson A; Horvath LB; Carnegie PR
J Neurosci Res; 1981; 6(5):567-78. PubMed ID: 6172593
[TBL] [Abstract][Full Text] [Related]
46. Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis.
Warren KG; Catz I
J Neuroimmunol; 1993 Mar; 43(1-2):87-96. PubMed ID: 7681451
[TBL] [Abstract][Full Text] [Related]
47. Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis.
Olsson T; Baig S; Höjeberg B; Link H
Ann Neurol; 1990 Feb; 27(2):132-6. PubMed ID: 1690527
[TBL] [Abstract][Full Text] [Related]
48. Optic neuritis and multiple sclerosis: the T cell repertoires to myelin proteins and MBP peptides change with time.
Söderström M; Link H; Fredrikson S; Sun JB
Acta Neurol Scand; 1994 Jul; 90(1):10-8. PubMed ID: 7524258
[TBL] [Abstract][Full Text] [Related]
49. Optic neuritis anti-myelin basic protein synthetic peptide specificity.
Warren KG; Catz I; Shutt K
J Neurol Sci; 1992 May; 109(1):88-95. PubMed ID: 1381412
[TBL] [Abstract][Full Text] [Related]
50. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls.
Hellings N; Barée M; Verhoeven C; D'hooghe MB; Medaer R; Bernard CC; Raus J; Stinissen P
J Neurosci Res; 2001 Feb; 63(3):290-302. PubMed ID: 11170179
[TBL] [Abstract][Full Text] [Related]
51. Determination of the sequential degradation of myelin proteins by macrophages.
van der Goes A; Boorsma W; Hoekstra K; Montagne L; de Groot CJ; Dijkstra CD
J Neuroimmunol; 2005 Apr; 161(1-2):12-20. PubMed ID: 15748939
[TBL] [Abstract][Full Text] [Related]
52. CSF antibodies to myelin basic protein and to myelin-associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies.
Wajgt A; Górny M
Acta Neurol Scand; 1983 Nov; 68(5):337-43. PubMed ID: 6198864
[TBL] [Abstract][Full Text] [Related]
53. The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis.
Warren KG; Catz I
Ann Neurol; 1985 May; 17(5):475-80. PubMed ID: 2408558
[TBL] [Abstract][Full Text] [Related]
54. Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS.
Tomassini V; De Giglio L; Reindl M; Russo P; Pestalozza I; Pantano P; Berger T; Pozzilli C
Mult Scler; 2007 Nov; 13(9):1086-94. PubMed ID: 17468447
[TBL] [Abstract][Full Text] [Related]
55. Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis.
Chou YK; Bourdette DN; Offner H; Whitham R; Wang RY; Hashim GA; Vandenbark AA
J Neuroimmunol; 1992 May; 38(1-2):105-13. PubMed ID: 1374422
[TBL] [Abstract][Full Text] [Related]
56. Myelin basic protein and its antibodies in the cerebrospinal fluid in experimental allergic encephalomyelitis, multiple sclerosis and other diseases.
Alvord EC; Hruby S; Shaw CM; Slimp J
Prog Clin Biol Res; 1984; 146():359-63. PubMed ID: 6201907
[TBL] [Abstract][Full Text] [Related]
57. Measurement of immunoreactive myelin basic protein peptide (45-89) in cerebrospinal fluid.
Gupta MK; Whitaker JN; Johnson C; Goren H
Ann Neurol; 1988 Mar; 23(3):274-80. PubMed ID: 2454068
[TBL] [Abstract][Full Text] [Related]
58. Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.
Wajgt A; Górny M; Szczechowski L; Grzybowski G; Ochudło S
Acta Med Pol; 1989; 30(3-4):121-8. PubMed ID: 2485126
[TBL] [Abstract][Full Text] [Related]
59. Optic neuritis and multiple sclerosis: anti-MBP and anti-MBP peptide antibody-secreting cells are accumulated in CSF.
Söderström M; Link H; Xu Z; Fredriksson S
Neurology; 1993 Jun; 43(6):1215-22. PubMed ID: 7513391
[TBL] [Abstract][Full Text] [Related]
60. Immunoreactive myelin proteolipid, protein-like activity in cerebrospinal fluid and serum of neurologically impaired patients.
Trotter JL; Wegescheide CL; Garvey WF
Ann Neurol; 1983 Nov; 14(5):554-8. PubMed ID: 6197007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
